Semacare Closes ￥10M Series A Financing

According to VCBeat, recently, Shenzhen Semacare Medical Technology Co., Ltd. ("Semacare") completed its Series A round of tens of millions from Shenzhen Lihe Hongxin Venture Capital. Proceeds from the financing will be used for mass production. At present, Semacare is planning for a new round of financing.

Previously, Semacare obtained an investment of 10 million yuan in Pre-A round from ISVI.

Established in November 2014 in Melbourne, Australia, Semacare, formerly known as Semeijia Medical, is an innovative medical technology company committed to integrating clinical data with artificial intelligence and machine learning technology. Semacare focuses on the field of cardiovascular diseases, with the core business of chronic disease prevention and management.

At present, Semacare mainly provides the integrated solution of "hardware+software+diagnosis+ management" in the cardiovascular field.

Wang Boyang, CEO of Semacare, thinks that the cardiovascular and cerebrovascular market is still in the growth stage, and the future growth point will be the solution from the hospital to the family. At present, the market of families is still under development, and Semacare takes the lead to enter, which will make up the gap in the market.

In order to realize the company's vision, Semacare has launched LifeStudy™, LifeService™, Zhixintie™, and other products based on big data, artificial intelligence and other technologies. LifeStudy™ (of data science) and LifeService™ (of data services) with the combination of hardware products (the front-end data monitoring) can realize the all-in-one service model integrating prevention, early diagnosis and treatment and build a closed-loop business.

In addition to the product portfolio, the team at Semacare is an essential part of its development, which is composed of innovative medical hardware and software R&D experts and marketing personnel from all over the world. Most of them have worked in top enterprises, such as Huawei, Mindray, Google, Microsoft, etc.

Founded in 2016, Lihe Hongxin focuses on investment in biological medicine, new energy, new materials, electronic information, integrated circuit, high-end equipment and other emerging industries. The company mainly participated in early-stage financing and currently has invested more than 50 projects.